ibi133
Locally Advanced Unresectable or Metastatic Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.Phase 1/2Active
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 95/ 100
Competitive context
7 Active assets in the Locally Advanced Unresectable or Metastatic Solid Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ibi354 Innovent Biologics (Suzhou) Co. Ltd. | Phase 1/2 | CCC |
sg1906 Hangzhou Sumgen Biotech Co., Ltd. | Phase 1 | CC |
Irinotecan Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 | CC |
Eloxatin Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 | CC |
ibi343 Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 | CC |
Calcium folinate pentahydrate Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 | CC |
FLUOROURACILUM Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 | CC |
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →